ArticleMolecular medicine reports2019
MicroRNA‑22 alleviates inflammation in ischemic stroke via p38 MAPK pathways.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- A systematic review of the research progress of non-coding RNA in neuroinflammation and immune regulation in cerebral infarction/ischemia-reperfusion injury.Frontiers in immunology · 2022Pooled it
- Altered expression of miRNAs and its implication for Pseudomonas aeruginosa keratitis.Indian journal of ophthalmology · 2026Article
- Tetrahedral framework nucleic acids: Nanokeys unlocking a new era of precision biomedicine.Journal of advanced research · 2026Review
- Decreased circulating microRNA-22 expression as a potential biomarker for predicting a higher risk of recurrent ischemic stroke related to inner carotid artery stenosis: a multicenter study.Journal of thrombosis and thrombolysis · 2025Article
- The ability of microRNAs to regulate the immune response in ischemia/reperfusion inflammatory pathways.Genes and immunity · 2024Review
- Effect of scutellarin on BV-2 microglial-mediated apoptosis in PC12 cells via JAK2/STAT3 signalling pathway.Scientific reports · 2024Article
- 5-Hydroxymethylfurfural Ameliorates Allergic Inflammation in HMC-1 Cells by Inactivating NF-κB and MAPK Signaling Pathways.Biochemical genetics · 2024Article
- MicroRNA Profiles in Critically Ill Patients.Current medicinal chemistry · 2024Review
- Scutellarin Acts via MAPKs Pathway to Promote M2 Polarization of Microglial Cells.Molecular neurobiology · 2023Article
- MicroRNA: Crucial modulator in purinergic signalling involved diseases.Purinergic signalling · 2023Review
- Role and regulatory mechanism of microRNA mediated neuroinflammation in neuronal system diseases.Frontiers in immunology · 2023Review
- Microglia activation in central nervous system disorders: A review of recent mechanistic investigations and development efforts.Frontiers in neurology · 2023Review
- MicroRNA-22: a Novel and Potent Biological Therapeutics in Neurological Disorders.Molecular neurobiology · 2022Review
- Detecting Key Functional Components Group and Speculating the Potential Mechanism of Xiao-Xu-Ming Decoction in Treating Stroke.Frontiers in cell and developmental biology · 2022Article
- Naoluo Xintong Decoction in the Treatment of Ischemic Stroke: A Network Analysis of the Mechanism of Action.Frontiers in pharmacology · 2022Article
- miRNA Involvement in Cerebral Ischemia-Reperfusion Injury.Frontiers in neuroscience · 2022Review
- Exploration of the mechanism of luteolin against ischemic stroke based on network pharmacology, molecular docking and experimental verification.Bioengineered · 2021Article
- Phenothiazine Inhibits Neuroinflammation and Inflammasome Activation Independent of Hypothermia After Ischemic Stroke.Molecular neurobiology · 2021Article
- MiRNA: Involvement of the MAPK Pathway in Ischemic Stroke. A Promising Therapeutic Target.Medicina (Kaunas, Lithuania) · 2021Review
- miR-19a/b-3p promotes inflammation during cerebral ischemia/reperfusion injury via SIRT1/FoxO3/SPHK1 pathway.Journal of neuroinflammation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to ascertain the potential roles and mechanisms of action of micro (mi)RNA‑22 in ischemic stroke. The results indicated that miRNA‑22 expression was downregulated in ischemic stroke rats model, compared with a control group. The downregulation of miRNA‑22 upregulated the expression of inflammatory factors [including tumor necrosis factor‑α, interleukin (IL)‑1β, IL‑6 and IL‑18]. It could also induce the expression of macrophage inflammatory protein (MIP‑2), prostaglandin E2 (PGE2), cyclooxygenase‑2 (COX‑2) and inducible NO synthase (iNOS) in the in vitro model. By contrast, the overexpression of miRNA‑22 downregulated the expression of inflammatory factors, and suppressed the expression of MIP‑2, PGE2, COX‑2 and iNOS in the in vitro model. The downregulation of miRNA‑22 induced the protein expression of nuclear factor (NF)‑κB and phosphorylated‑p38 (p‑p38) mitogen‑activated protein kinase (MAPK) in the in vitro model. By comparison, the overexpression of miRNA‑22 suppressed the protein expression of NF‑κB and p‑p38 in the in vitro model. Typically, LY2228820, the p38 inhibitor (3 nM) would mitigate the pro‑inflammatory effects of anti‑miRNA‑22 in the in vitro model. These results suggested that miRNA‑22 can alleviate ischemic stroke‑induced inflammation in rats model or vitro model through p38 MAPK/NF‑κB pathway suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.